Patient Selection For Analgesic Trials To Be Improved Under Public-Private ACTION Initiative
Executive Summary
A new collaborative project between FDA and the University of Rochester could help drugmakers salvage pain drugs that have garnered negative clinical trial results but may have efficacy in a narrower population by creating more sensitive assays.
You may also be interested in...
Efficacy Standards For 55 Diseases In 5 Years: FDA, Critical Path And CDISC’s Ambitious Plan
Building on the Alzheimer’s disease Therapeutic Area Standard, the groups hope to create measurement standards for clinical trials in a variety of therapeutic areas, but funding remains an acute challenge. In order to succeed, each project needs to be faster and cheaper than the Alzheimer’s effort.
Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns
Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.